# Yoltech Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yoltech-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.yoltx.com/
- Total disclosed funding: $148M
- Latest round: Series C (May 29, 2026)
- Investors on record: 15

## About

Based in Shanghai, China, and founded in 2021, Shanghai Yaotang Biotechnology Co., Ltd., trading as Yoltech Therapeutics, is a biotech company committed to developing gene-editing drugs against hereditary diseases and cardiovascular diseases. The company's founder, Dr. Yuxuan Wu, graduated from East China Normal University. In May 2026, Yoltech Therapeutics raised nearly CNY 500 million in series C funding led by Loyal Valley Capital, with participation from Shanghai State-owned Capital Investment Leading Fund, Shanghai Minhang Financial Investment Development, Deyue Investment, K2VC, Grand Flight Investment, Tianjin Venture Capital and other investors.

The company focuses on the development of mRNA drugs and gene editing drugs by improving mRNA production platforms and lipid nanocarrier assembly processes through CRISPR, base editing and other gene editing tools. The current pipeline of products in development includes LNP in vitro delivery of gene edited drugs for metabolic diseases (familial hypercholesterolemia, etc.), genetic diseases (primary hyperoxaluria, etc.), and infectious diseases (hepatitis B, etc.). 

The company's revenue is generated by developing mRNA drugs and gene editing drugs.

## Funding rounds

- Series C, May 29, 2026, $74M — Tianjin Venture Capital, K2VC, Grand Flight Investment, Loyal Valley Capital, Deyue Investment, Shanghai State-owned Capital Investment Leading Fund, Shanghai Minhang Financial Investment Development
- Series B, Sep 10, 2025, $45M — China International Capital Corporation, Green Pine Capital Partners, Tianjin Venture Capital, Decheng Capital, K2VC, Grand Flight Investment, Beijing Xinneng Venture Capital
- Series A, Nov 30, 2023, $14M — Decheng Capital, Huafang Capital, Guangzhou Industry Investment Holding Group
- Series A, Aug 10, 2022, $15M — Unity Ventures, K2VC, Grand Flight Investment, Yinglian Health Industry Fund
- Angel, Feb 25, 2022 — K2VC

## Investors

- K2VC (https://capitalatlas.ai/funds/k2vc) — Angel, Series A, Series B, Series C
- Unity Ventures (https://capitalatlas.ai/funds/unity-ventures) — Series A
- Grand Flight Investment (https://capitalatlas.ai/funds/grand-flight-investment) — Series A, Series B, Series C
- Yinglian Health Industry Fund — Series A
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series A, Series B
- Huafang Capital (https://capitalatlas.ai/funds/huafang-capital) — Series A
- Guangzhou Industry Investment Holding Group (https://capitalatlas.ai/funds/guangzhou-industry-investment-holding-group) — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series B
- Tianjin Venture Capital (https://capitalatlas.ai/funds/tianjin-venture-capital) — Series B, Series C
- Beijing Xinneng Venture Capital (https://capitalatlas.ai/funds/beijing-xinneng-venture-capital) — Series B
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series C
- Deyue Investment (https://capitalatlas.ai/funds/deyue-investment) — Series C
- Shanghai State-owned Capital Investment Leading Fund (https://capitalatlas.ai/funds/shanghai-state-owned-capital-investment-leading-fund) — Series C
- Shanghai Minhang Financial Investment Development — Series C